Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment.
Hepatic arterial infusion chemotherapy
Hepatic arterial infusion chemotherapy with a port system
Hepatocellular carcinoma
Liver cancer
Liver metastases
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
27
06
2021
accepted:
04
04
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma is one of the leading causes of cancer-related death both in Japan and globally. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver cancer in Japan, and implantation of a catheter system (called a port system) in the body is a treatment method that has evolved mainly in Japan. The Guideline Committee of the Japanese Society of Interventional Radiology and the Japanese Society of Implantable Port Assisted Treatment jointly published clinical practice guidelines for HAIC with a port system to ensure its appropriate and safe performance in Japanese in 2018. We have written an updated English version of the guidelines with the aim of making this treatment widely known to experts globally. In this article, the evidence, method, indication, treatment regimen, and maintenance of the system are summarized.
Identifiants
pubmed: 36158592
doi: 10.1159/000524893
pii: lic-0011-0407
pmc: PMC9485983
doi:
Types de publication
Journal Article
Langues
eng
Pagination
407-425Informations de copyright
Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Kazuomi Ueshima received honoraria and consulting or advisory fees from Bayer AG, Eisai Co. Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Kowa Co., Ltd. and consulting or advisory fees from Eisai Co., Ltd., Eli Lilly and Company, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. Atsushi Komemushi, Takeshi Aramaki, Hideki Iwamoto, Shuntaro Obi, Yozo Sato, Toshihiro Tanaka, Kiyoshi Matsueda, Hiroya Saito, Miyuki Sone, and Yoshitaka Inaba have no relevant conflicts of interest to disclose. Michihisa Moriguchi received honoraria from Bayer, Eisai, Eli Lilly, and Chugai and consulting or advisory fees from Bayer, Eli Lilly, and Chugai. Takuji Yamagami received a research grant from Guerbet Japan, Nihon Medi-Physics, Eisai, Fujifilm Toyama Chemical Co. Ltd., GE Healthcare, Boston Scientific, and Fuji Pharma Co., Ltd. Masatoshi Kudo received honoraria and consulting or advisory fees from Bayer AG and Eisai Co., Ltd.; honoraria from Bayer AG, Bristol Myers Squibb, EA Pharma Co., Ltd., Eisai Co., Ltd., and Merck Sharp & Dohme; and research funding from Bayer AG, Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Merck Sharp & Dohme, Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., and Taiho Pharmaceutical. Yasuaki Arai received honoraria from Merit Medical Systems, Cosmotec, Fuji Pharma, Canon Medical Systems, Canon Medical Systems Asia Pte. Ltd., Canon Medical Systems Malaysia Sdn. Bhd., Sumitomo Bakelite, Boston Scientific Japan, Boston Scientific Corporation, Japan Lifeline, AstraZeneca plc, Guerbet Japan, Guerbet Asia Pacific, Kyorin Pharmaceutical, Daiichi Sankyo Co., Ltd., and Eisai Co., Ltd. Masatoshi Kudo is the Editor-in-Chief of Liver Cancer, and Kazuomi Ueshima is an Editorial Board Member of Liver Cancer.
Références
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Oncol Rep. 1999 May-Jun;6(3):587-91
pubmed: 10203596
AJR Am J Roentgenol. 2014 Jan;202(1):211-5
pubmed: 24370146
Surgery. 1982 Oct;92(4):706-12
pubmed: 7123491
Hepatol Res. 2012 Feb;42(2):150-65
pubmed: 22044786
Anticancer Res. 2016 Jul;36(7):3523-9
pubmed: 27354618
Jpn J Clin Oncol. 2017 Jun 01;47(6):512-519
pubmed: 28334948
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Sci. 2009 Jan;100(1):173-80
pubmed: 19037999
J Cancer Res Clin Oncol. 2011 Apr;137(4):659-67
pubmed: 20552225
Aliment Pharmacol Ther. 2010 Aug;32(4):543-50
pubmed: 20500734
Cancer. 2009 Nov 1;115(21):4990-9
pubmed: 19637365
Cancer Chemother Pharmacol. 2011 Mar;67(3):629-35
pubmed: 20495917
Cancer. 2006 May 1;106(9):1990-7
pubmed: 16565970
J Gastrointest Cancer. 2018 Jun;49(2):132-137
pubmed: 28058527
J Vasc Interv Radiol. 2010 Nov;21(11):1681-8
pubmed: 21029950
J Clin Oncol. 2000 Jan;18(2):243-54
pubmed: 10637236
J Comput Assist Tomogr. 1996 May-Jun;20(3):343-8
pubmed: 8626887
Oncology. 2011;81(5-6):281-90
pubmed: 22133996
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Clin J Gastroenterol. 2009 Feb;2(1):47-50
pubmed: 26191809
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
J Vasc Interv Radiol. 2012 Aug;23(8):997-1007
pubmed: 22840801
Surg Today. 2009;39(10):905-8
pubmed: 19784733
Hepatogastroenterology. 2003 Jan-Feb;50(49):49-53
pubmed: 12629988
Am J Med. 1982 Dec;73(6):841-5
pubmed: 6959532
J Vasc Interv Radiol. 2001 Oct;12(10):1215-8
pubmed: 11585889
Cancer. 2002 Jan 15;94(2):435-42
pubmed: 11900229
Acta Radiol. 2016 Jul;57(7):781-8
pubmed: 26339040
Ann Surg. 1985 Aug;202(2):176-81
pubmed: 3160313
J Gastroenterol. 2005 Jan;40(1):70-8
pubmed: 15692792
J Vasc Interv Radiol. 2012 Oct;23(10):1261-7
pubmed: 22922040
J Clin Oncol. 2005 Aug 1;23(22):4881-7
pubmed: 16009952
AJR Am J Roentgenol. 2005 Mar;184(3):906-14
pubmed: 15728616
Cancer Chemother Pharmacol. 1997;40(6):526-30
pubmed: 9332468
Hepatol Res. 2014 Nov;44(12):1179-85
pubmed: 24171787
Med Oncol. 2015 Mar;32(3):65
pubmed: 25691293
Hepatol Res. 2012 May;42(5):442-53
pubmed: 22176468
Mol Clin Oncol. 2017 Dec;7(6):1013-1020
pubmed: 29285366
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Formos Med Assoc. 2021 Apr;120(4):1051-1060
pubmed: 33199101
AJR Am J Roentgenol. 2012 Apr;198(4):923-30
pubmed: 22451562
Asia Pac J Clin Oncol. 2015 Mar;11(1):41-8
pubmed: 25628061
Oncology. 2011;80(1-2):63-9
pubmed: 21659784
World J Surg Oncol. 2007 Jun 21;5:70
pubmed: 17584926
J Cancer Res Ther. 2017 Jan-Mar;13(1):84-90
pubmed: 28508838
J Gastroenterol. 2012 Jun;47(6):686-95
pubmed: 22382631
Liver Cancer. 2017 Nov;6(4):275-286
pubmed: 29234631
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50
pubmed: 26754678
Jpn J Radiol. 2014 Nov;32(11):670-5
pubmed: 25260991
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Surg Oncol. 2016 Nov;114(6):655-663
pubmed: 27566258
JAMA Oncol. 2019 Jul 1;5(7):953-960
pubmed: 31070690
Cancer. 2007 Jul 1;110(1):129-37
pubmed: 17508408
Clin Colorectal Cancer. 2010 Dec;9(5):305-10
pubmed: 21208845
Tech Vasc Interv Radiol. 2007 Mar;10(1):30-7
pubmed: 17980316
Liver Int. 2007 Nov;27(9):1209-16
pubmed: 17919232
Clin Radiol. 1999 Apr;54(4):221-7
pubmed: 10210340
Cancer Chemother Pharmacol. 1992;31 Suppl:S99-102
pubmed: 1458567
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Oncology. 1999 Oct;57(3):216-23
pubmed: 10545790
Cardiovasc Intervent Radiol. 2018 May;41(5):734-743
pubmed: 29327075
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Cancer Med. 2015 Aug;4(8):1214-23
pubmed: 26044168
World J Gastroenterol. 2013 Aug 7;19(29):4679-88
pubmed: 23922465
J Gastroenterol Hepatol. 2012 Dec;27(12):1850-7
pubmed: 23020312
Br J Cancer. 2005 Sep 5;93(5):557-64
pubmed: 16106266
Ann Oncol. 2021 Jun;32(6):801-805
pubmed: 33716105
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
J Clin Oncol. 2006 Mar 20;24(9):1395-403
pubmed: 16505413
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Vasc Interv Radiol. 2005 Dec;16(12):1747-51
pubmed: 16371545
Gan To Kagaku Ryoho. 1982 Oct;9(10):1838-43
pubmed: 7184378
J Cancer Res Clin Oncol. 2017 Oct;143(10):2131-2141
pubmed: 28646261
Int J Gastrointest Cancer. 2001;30(3):147-60
pubmed: 12540027
World J Gastroenterol. 2005 Sep 28;11(36):5685-7
pubmed: 16237765
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Jpn J Clin Oncol. 2018 Feb 1;48(2):103-114
pubmed: 29253194
Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4
pubmed: 8137476
Gan To Kagaku Ryoho. 2010 Aug;37(8):1615-6
pubmed: 20716900
J Vasc Interv Radiol. 2003 Jan;14(1):63-8
pubmed: 12525587
Jpn J Clin Oncol. 2002 Feb;32(2):68-70
pubmed: 11948232
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786
pubmed: 29645345
J Hepatol. 2018 Jul;69(1):60-69
pubmed: 29471013
Hepatol Res. 2005 Jun;32(2):127-33
pubmed: 15869904
J Gastroenterol. 2015 Apr;50(4):445-54
pubmed: 25027973
Oncology. 2002;62 Suppl 1:69-73
pubmed: 11868789
Cancer. 2004 Feb 1;100(3):590-7
pubmed: 14745877
Oncology. 2010 Jul;78 Suppl 1:148-53
pubmed: 20616598
Mol Clin Oncol. 2013 Sep;1(5):869-874
pubmed: 24649263
Cancer. 2002 Aug 1;95(3):588-95
pubmed: 12209752
J Clin Oncol. 2020 Dec 20;38(36):4317-4345
pubmed: 33197225
Tumori. 2003 Jul-Aug;89(4):382-4
pubmed: 14606639
Cancer Sci. 2016 Sep;107(9):1263-9
pubmed: 27315783
Ann Oncol. 2016 Nov;27(11):2090-2096
pubmed: 27573564
J Comput Assist Tomogr. 1989 Nov-Dec;13(6):958-64
pubmed: 2584507
Br J Cancer. 2013 Oct 1;109(7):1904-7
pubmed: 24008659
Chin J Cancer. 2017 Oct 23;36(1):83
pubmed: 29061175
Cancer. 1992 Jan 15;69(2):327-34
pubmed: 1303612
J Clin Oncol. 2006 Aug 20;24(24):3939-45
pubmed: 16921046